Outcomes in COVID-19 aviptadil studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -5% 3 775 Improvement, Studies, Patients Relative Risk Mortality 16% 2 657 Progression 15% 2 657 RCTs -5% 3 775 RCT mortality 16% 2 657 Peer-reviewed 16% 2 657 Late -5% 3 775 Aviptadil for COVID-19 c19early.org December 2025 Favorsaviptadil Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY Gibbs (DB RCT) -79% 1.79 [1.12-2.94] no recov. 51 (n) 67 (n) Improvement, RR [CI] Treatment Control COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) Tau​2​ = 0.17, I​2​ = 82.6%, p = 0.87 Late treatment -5% 1.05 [0.63-1.74] 46/413 30/362 5% higher risk All studies -5% 1.05 [0.63-1.74] 46/413 30/362 5% higher risk 3 aviptadil COVID-19 studies c19early.org December 2025 Tau​2​ = 0.17, I​2​ = 82.6%, p = 0.87 Effect extraction pre-specified(most serious outcome) Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] 46/131 30/65 Improvement, RR [CI] Treatment Control TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] 231 (n) 230 (n) Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Late treatment 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk All studies 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk 2 aviptadil COVID-19 mortality results c19early.org December 2025 Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 Improvement, RR [CI] Treatment Control TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Late treatment 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk All studies 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk 2 aviptadil COVID-19 serious outcomes c19early.org December 2025 Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Effect extraction pre-specified(most serious outcome) Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY Gibbs (DB RCT) -79% 1.79 [1.12-2.94] no recov. 51 (n) 67 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.018 Late treatment -79% 1.79 [1.12-2.94] 51 (n) 67 (n) 79% higher risk All studies -79% 1.79 [1.12-2.94] 51 (n) 67 (n) 79% higher risk 1 aviptadil COVID-19 recovery result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.018 Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY Gibbs (DB RCT) -79% 1.79 [1.12-2.94] no recov. 51 (n) 67 (n) Improvement, RR [CI] Treatment Control COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) Tau​2​ = 0.17, I​2​ = 82.6%, p = 0.87 Late treatment -5% 1.05 [0.63-1.74] 46/413 30/362 5% higher risk All studies -5% 1.05 [0.63-1.74] 46/413 30/362 5% higher risk 3 aviptadil COVID-19 Randomized Controlled Trials c19early.org December 2025 Tau​2​ = 0.17, I​2​ = 82.6%, p = 0.87 Effect extraction pre-specified(most serious outcome) Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] 46/131 30/65 Improvement, RR [CI] Treatment Control TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] 231 (n) 230 (n) Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Late treatment 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk All studies 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk 2 aviptadil COVID-19 RCT mortality results c19early.org December 2025 Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 Improvement, RR [CI] Treatment Control TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Late treatment 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk All studies 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk 2 aviptadil COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Effect extraction pre-specified(most serious outcome) Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY Gibbs (DB RCT) -79% 1.79 [1.12-2.94] no recov. 51 (n) 67 (n) Improvement, RR [CI] Treatment Control COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 COVID-AIV Youssef (DB RCT) 20% 0.80 [0.52-1.13] progression 59/131 31/65 TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) TESICO Brown (DB RCT) 10% 0.90 [0.65-1.25] progression 231 (n) 230 (n) Aviptadil COVID-19 outcomes c19early.org December 2025 Favors aviptadil Favors control